Retatrutide TRIUMPH-1 Phase 3 Results: Weight Loss Data, Endpoints & Researcher Summary

Retatrutide TRIUMPH-1 Phase 3 Results: What Researchers Need to Know

On May 21, 2026, Eli Lilly announced topline results from TRIUMPH-1 — the pivotal Phase 3 obesity trial of retatrutide (LY3437943), a triple agonist targeting the GLP-1, GIP, and glucagon receptors simultaneously. The results represent the largest weight reduction magnitude reported in any pharmacological obesity trial to date and mark a significant escalation from the compound's Phase 2 data. This post summarizes the published trial data in research context. All content is presented for informational and research reference purposes only and does not constitute medical advice or guidance for human use.

Trial Design: TRIUMPH-1

Compound: Retatrutide (LY3437943), once-weekly subcutaneous injection
Population: 2,339 adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity, without type 2 diabetes
Duration: 80 weeks (primary endpoint); pre-specified blinded extension to 104 weeks in participants with BMI ≥ 35 who completed the main trial
Arms: 4 mg, 9 mg, and 12 mg weekly doses vs. placebo
Sponsor: Eli Lilly and Company
Announcement date: May 21, 2026

Primary Results at 80 Weeks

All three active dose arms met the trial's primary and key secondary endpoints versus placebo. Weight change from baseline at 80 weeks:

At the 12 mg dose, participants lost an average of approximately 28.3% of body weight — roughly 70 lbs (31.9 kg) for a participant starting at 250 lbs — based on data reported across multiple trial coverage sources citing the Lilly press release and Pharmaceutical Journal coverage.

104-Week Extension Data

In a pre-specified blinded extension enrolling participants with BMI ≥ 35 who completed the 80-week trial and tolerated their assigned medication, the 12 mg arm reached a mean body weight reduction of 30.3% at 104 weeks — a continued trajectory not seen in earlier GLP-1 class agents, where weight loss generally plateaued by 52–72 weeks.

Safety and Tolerability

The safety profile was consistent with the GLP-1 receptor agonist class and with retatrutide's Phase 2 findings (NEJM, Jastreboff et al., 2023; PMID 41997446):

• Most common adverse events: Nausea, vomiting, diarrhea, and constipation — predominantly mild-to-moderate, most frequent during dose escalation
• Discontinuation due to adverse events: 11.3% in the high-dose (12 mg) arm vs. 4.9% in the placebo group
• Heart rate: Small increases of 3–5 bpm consistent with GLP-1 class effect
• Liver function: No clinically significant adverse liver function signals emerged despite the glucagon receptor component, which had been flagged as a theoretical concern given glucagon's hepatic metabolic effects

The discontinuation rate at the 12 mg dose (11.3%) is higher than that seen with tirzepatide at its highest approved dose in SURMOUNT-1 (approximately 6.2%), which researchers have noted as a tolerability consideration distinguishing the two compounds.

Contextualizing the Results: Phase 3 vs. Phase 2

The TRIUMPH-1 Phase 3 results extend and in some metrics exceed the Phase 2 data:

The continued weight loss trajectory at 104 weeks — rather than the plateau observed with semaglutide and tirzepatide within trial windows — is among the most scientifically notable findings, and has prompted comparisons to bariatric surgery outcomes (typically −25–35% total weight loss) in research commentary.

Comparison to Other Approved and Investigational GLP-1 Class Agents

For research context, the TRIUMPH-1 data positions retatrutide at the upper end of the weight loss spectrum among incretin-based pharmacological research:

• Semaglutide (STEP 1, 68 weeks): −14.9% (PMID 42027588)
• Tirzepatide (SURMOUNT-1, 72 weeks, 15 mg): −20.9% (PMID 42029986)
• Retatrutide (TRIUMPH-1, 80 weeks, 12 mg): −25.0% to −28.3%

The additional weight loss relative to tirzepatide has been attributed in preclinical mechanistic research to the glucagon receptor component — specifically, increased resting energy expenditure via hepatic fatty acid oxidation and thermogenesis — effects that GLP-1/GIP dual agonism alone does not capture (Finan et al., Science Translational Medicine, 2015).

Regulatory Timeline

Eli Lilly maintained its NDA submission guidance of late 2026 to Q1 2027 at its Q1 2026 earnings call. If approved, retatrutide would enter a GLP-1 obesity therapy market alongside semaglutide (Wegovy) and tirzepatide (Zepbound), with a differentiated position based on its triple-receptor mechanism and the magnitude of weight loss observed in TRIUMPH-1.

Regulatory researchers should note that the FDA's May 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list signals the agency's expectation that commercially-available branded GLP-1 agents — including a potential approved retatrutide — will be the primary access pathway rather than compounded alternatives. See the FDA 503B GLP-1 exclusion analysis for research context.

Ongoing TRIUMPH Program

TRIUMPH-1 is one arm of Lilly's broader Phase 3 retatrutide program:

• TRIUMPH-1: Obesity without T2D (results reported May 2026)
• TRIUMPH-2: Type 2 diabetes indication (ongoing)
• TRIUMPH-3: MASH (metabolic dysfunction-associated steatohepatitis; ongoing)
• TRIUMPH-4: Obesity with knee osteoarthritis — results reported December 2025 showed −28.7% weight loss at 68 weeks at 12 mg

The TRIUMPH-3 MASH arm is of particular research interest given retatrutide's hepatic mechanism of action via glucagon receptor signaling, which is mechanistically relevant to the hepatic fat accumulation underlying MASH pathophysiology.

Key References

• Jastreboff, A.M. et al. (2023). "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with obesity." New England Journal of Medicine. PMID: 41997446
• Lilly press release (May 21, 2026). "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial." PR Newswire.
• Pharmaceutical Journal (May 2026). "Phase III retatrutide study demonstrates 30% weight loss."
• Finan, B. et al. (2015). "Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans." Science Translational Medicine. PMID: 26582901
• FDA Federal Register (May 2026). "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List." Docket 2026-08552.

See also: Retatrutide compound library entry · Retatrutide vs Tirzepatide comparison · Semaglutide vs Retatrutide research comparison

All content on ClinicalPeptide.org is intended for researchers and educators working in pharmacology, biochemistry, and related disciplines. This post summarizes publicly reported clinical trial results for research reference only. Nothing on this site constitutes medical advice.